Excited to share our latest publication assessing the role of Ravulizumab to treat complement cascade over-activation in patients with AKI in the setting of COVID-19 infection.
@AlizaAnwarMemo1@SiedleckiAndrew@BrighamResearch#MedTwitter
A Randomized Control Trial of Ravulizumab for Treatment of Patients with COVID-19 Infection and Kidney Injury. 2022 from @KIReports@HasbanAhmed
➡️ https://t.co/jNO7vnNufy
"One more thing," the patient says, right when I'm about to exit the exam room.
I used to be annoyed by it. Until one day, a patient's "one more thing" was actually "the" thing she wanted to say. But she needed to feel me out and make sure I was a safe person first. So, I sat back down and listened. Then we discussed and ran tests.
"You restored my faith in doctors." She took the bus just to tell me this today after making a full recovery. Her visit filled my heart with warmth and purpose.
If we ask people to wait for months for their appointments, then (sometimes) hours in our offices, we can hear them out for their one more thing.
THIS IS A CROSS BORDER APPEAL! ⚠️
Professor Dr. Irshad Hussain Qureshi, Ex HOD Medicine of MHL , Ex Registrar KEMU, has been diagnosed with Gastric Carcinoma for which he needs a drug Cyramza (Ramucirumab) IV not available in Pakistan, but in India. 1/n
Been thinking about this a lot. I think it’s really important to look at your achievements from a perspective of when you didn’t have them.
Yes looking forward is important. But so is appreciating yourself for overcoming obstacles.
All milestones should be celebrated.
Kemcolians' Graduate Diaries, on behalf of all Kemcolians, congratulates Dr. Asif Bashir (Class of 1995) and Dr. Afzal Javed (Class of 1997) for being awarded the Tamgha-e-Imtiaz and Sitara-e- Imtiaz respectively, for their exceptional contribution to the field of medicine.